## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-carpal-tunnel`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-carpal-tunnel` v2 · content_hash `34ad1005da6b76d7…` · thread_head genesis · 19 DIVs
- **thesis (c1):** No published human trials examine SS-31 in carpal tunnel syndrome.
  - c2 [human/active] A phase 1/2 randomized trial in 36 adults with primary mitochondrial myopathy showed dose-dependent improvement in exercise performance after 5 days of elamipre
  - c5 [human/active] Human trials in Barth syndrome and renal artery stenosis reported improvements in functional measures and perfusion after SS-31.
  - c3 [preclinical/active] Preclinical spinal cord injury models showed SS-31 reduced neuronal death and supported recovery via cardiolipin preservation.
  - c4 [mechanistic/active] SS-31 binds cardiolipin to stabilize mitochondrial membrane and support ATP production.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-carpal-tunnel`
- **title:** SS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidence Review
- **url:** https://miscsubjects.com/a/ss-31-carpal-tunnel
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:01.604Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Carpal tunnel syndrome

Carpal tunnel syndrome involves compression of the median nerve at the wrist. This creates local ischemia and mechanical stress on nerve fibers and surrounding tissues. Ischemia can impair mitochondrial energy production in affected cells. Oxidative stress rises when mitochondria fail to handle reactive oxygen species properly. Over time, this shifts the balance toward degeneration if repair pathways cannot keep pace. Swelling and fibrosis can further restrict blood flow and nutrient delivery. Mitochondrial dysfunction appears in various compression and ischemic nerve models as a contributing layer, though direct causation in human carpal tunnel remains under study.

## Why SS-31 (Elamipretide) might help you

1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.
2. Therefore for you: If mitochondrial stress from ischemia or compression is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

SS-31 binds to cardiolipin in the inner mitochondrial membrane. This stabilizes membrane structure and supports electron transport chain efficiency. Better ATP production could aid cellular maintenance in energy-demanding nerve tissue. Reduced cardiolipin peroxidation limits oxidative damage that might otherwise accelerate nerve fiber decline. In if-then terms: if compression creates hypoxic conditions that impair mitochondria, then preserving cardiolipin function addresses one upstream degenerative layer rather than downstream symptoms alone.

## How these fit together

Single-compound focus. SS-31 (Elamipretide) maps to the mitochondrial layer. No sibling peptides appear in scope, so no additional layers are addressed here.

## What the evidence actually shows

No published human trials examine SS-31 specifically in carpal tunnel syndrome (mechanistic/speculative for this condition). Human data come from other mitochondrial disorders. A phase 1/2 randomized dose-escalation trial in 36 adults with primary mitochondrial myopathy found dose-dependent improvement in exercise performance after 5 days of elamipretide (human tier). A phase 2/3 trial in Barth syndrome patients showed improvements in 6-minute walk test and cardiac stroke volume after longer exposure (human tier). A phase 2a trial in atherosclerotic renal artery stenosis patients reported better renal blood flow and cortical perfusion after SS-31 infusion versus placebo (human tier). Preclinical work includes an in vitro and in vivo spinal cord injury model where SS-31 reduced neuronal death, preserved cardiolipin, and supported behavioral recovery (preclinical tier). Another mouse study on spinal cord injury found no protection against acute muscle atrophy despite mitochondrial targeting (preclinical tier, negative result).

## What scientists say

Researchers describe SS-31 as a cardiolipin-targeting tetrapeptide that improves mitochondrial respiration and reduces oxidative stress in failing human heart mitochondria ex vivo (mechanistic tier). Reviews note its progression through multiple phase 2 and 3 trials for mitochondrial myopathies and heart failure, with mixed but generally favorable safety signals in those populations (human tier). No statements address carpal tunnel directly.

## What people say on Reddit

Anecdotal reports mention SS-31 in contexts of chronic fatigue or mitochondrial symptoms, with some users describing improved energy or reduced neurological complaints after use (anecdotal tier). No posts specifically reference carpal tunnel or wrist nerve compression. One user noted perceived nerve-related improvements in mobility after weeks of use, but this remains self-reported and unverified (anecdotal tier).

## What people say on X

Searches yielded no direct user reports linking SS-31 to carpal tunnel symptoms or outcomes. Broader discussion centers on its mitochondrial mechanism in rare disease contexts (anecdotal tier, absent for this condition).

## What we do not know

Direct evidence for SS-31 in carpal tunnel syndrome is absent. Human trials have not measured nerve conduction, symptom scores, or imaging changes in median nerve compression. Duration of effect, optimal timing relative to compression onset, and interaction with standard conservative measures remain untested. Translation from spinal cord injury or myopathy models to peripheral compression neuropathy is speculative.

## Safety and limits

In human trials, SS-31 was generally well tolerated. Common observations included injection site reactions. Phase trials in mitochondrial myopathy and Barth syndrome reported no serious adverse events tied to the peptide itself beyond local effects (human tier). It carries orphan drug and fast-track designations for certain mitochondrial conditions. Availability outside trials is limited. All claims here are for research context only; this is not medical advice.

## Claims (5)

- **c1** [mechanistic w=0.3] No published human trials examine SS-31 in carpal tunnel syndrome.
  - who_claims: grok/grok-4.3
- **c4** [mechanistic w=0.3] SS-31 binds cardiolipin to stabilize mitochondrial membrane and support ATP production.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c2** [human w=0.8] A phase 1/2 randomized trial in 36 adults with primary mitochondrial myopathy showed dose-dependent improvement in exercise performance after 5 days of elamipretide.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c5** [human w=0.8] Human trials in Barth syndrome and renal artery stenosis reported improvements in functional measures and perfusion after SS-31.
  - who_claims: grok/grok-4.3
  - sources: s4, s5
- **c3** [preclinical w=0.5] Preclinical spinal cord injury models showed SS-31 reduced neuronal death and supported recovery via cardiolipin preservation.
  - who_claims: grok/grok-4.3
  - sources: s2

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `221a87590549c4a3`

### s1 · pubmed · ok
- title: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
- url: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
- summary: Phase 1/2 RCT showing dose-dependent exercise gains in PMM patients.
- quote: Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.
- claim_ids: c2
- hash: `3bf13bf6e7700f84`

### s2 · pubmed · http_403
- title: Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury
- url: https://www.mdpi.com/1422-0067/26/7/3327
- summary: Preclinical SCI study with neuroprotection and cardiolipin data.
- quote: SS-31 not only mitigates acute mitochondrial dysfunction but also promotes long-term functional recovery, possibly by preserving neuronal...
- claim_ids: c3
- hash: `8cef5c370f6c4d7a`

### s3 · pubmed · ok
- title: Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
- summary: Mechanism review confirming cardiolipin binding and mitochondrial effects.
- quote: Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin (CL) on the inner mitochondrial membrane.
- claim_ids: c4
- hash: `786a9f4495eed3a9`

### s4 · pubmed · ok
- title: SS-31 treatment ameliorates cardiac mitochondrial dysfunction in a mouse model of Barth syndrome
- url: https://www.nature.com/articles/s41598-024-64368-y
- summary: Barth syndrome trial data on functional and cardiac improvements.
- quote: The collected data showed that a long exposure to the peptide (48 weeks) resulted in a significant improvement in performance on the 6-Minute Walk Test...
- claim_ids: c5
- hash: `aa0deaccbd0d5431`

### s5 · pubmed · ok
- title: SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Injury
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
- summary: Renal stenosis trial showing perfusion benefits versus placebo.
- quote: In an atherosclerotic renal artery stenosis phase IIa clinical trial... only patients in the SS-31 group showed increased renal blood flow... and renal cortical perfusion.
- claim_ids: c5
- hash: `221a87590549c4a3`

## Provenance (2 model passes)
- chain valid: yes · head: `5531f44110f3ee5c`

- write · grok/grok-4.3 · 2026-06-29T23:59 · hash `f3f43bfd44bc`
- voxel_divide · owner · 2026-07-17T02:42 · hash `5531f44110f3`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-carpal-tunnel","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-carpal-tunnel|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-carpal-tunnel|tier|assertion`
- **iMessage ask:** `ss-31-carpal-tunnel|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-carpal-tunnel`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-carpal-tunnel/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*